Ordering Recommendation

FDA-approved test for routine cervical cancer screening in combination with cervical cytology (pap smear) in individuals 30 years or older with a cervix. Follow-up test for abnormal cytology results in individuals 21 years or older with a cervix.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Females should avoid high concentrations of antifungal cream or contraceptive jelly, and should not douche prior to time of collection.


Cervical, anal, or vaginal specimen with brush or spatula from ThinPrep kit and place in PreservCyt Media

Specimen Preparation

Transport original ThinPrep or briefly vortex and transfer 1 mL to an Aptima Specimen Transfer Tube (ARUP supply #42711). Available online through eSupply using ARUP Connect ™ or contact ARUP Client Services at 800-522-2787. To reduce the potential for contamination, ThinPrep specimens should be poured off, using sterile technique, into the Aptima Specimen Transfer Tube prior to cytology testing.

Storage/Transport Temperature


Unacceptable Conditions

Bloody or dark brown specimens. Specimens in any media other than indicated above.


Specimen source required.


Ambient: 1 month; Refrigerated: 105 days; Frozen: Unacceptable


Qualitative Nucleic Acid Amplification (NAA)




1-5 days

Reference Interval


Interpretive Data

This test detects E6/E7 viral messenger RNA of 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) associated with cervical cancer and its precursor lesions. This test does not discriminate between the 14 high-risk HPV types. Sensitivity may be affected by specimen collection methods, stage of infection, and the presence of interfering substances. Results should be interpreted in conjunction with other available laboratory and clinical data. A negative high-risk HPV result does not exclude the presence of other high-risk HPV types.

HPV testing should not be used for screening or management of atypical squamous cells of undetermined significance (ASCUS) in women under age 21.

Compliance Category

Depends on Specimen/Source/Method


For cervical sources, a negative high-risk HPV result does not exclude the possibility of future cytologic abnormalities, underlying CIN2-3, or cancer.

Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
0060752 HPV Source 31208-2
2007891 HPV, High Risk by TMA 49896-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • HPV HR E6/E7 TMA
  • Nucleic Acid Amplification Test (NAAT) HPV PCR, HPV TMA
Human Papillomavirus (HPV) High Risk Screen, by Transcription-Mediated Amplification (TMA), ThinPrep